Immune T-cells of the CAR T-cell therapy CT103A are able to rapidly eliminate disease-driving immune cells and reduce immune cells’…
Articles by Marisa Wexler, MS
The risk of developing type 2 diabetes is more than 50% higher among people with neuromyelitis optica spectrum disorder…
None of the neuromyelitis optica spectrum disorder (NMOSD) patients in the Phase 3 CHAMPION-NMOSD clinical trial have had a…
The U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz) to treat adults with neuromyelitis optica spectrum…
People with neuromyelitis optica spectrum disorder (NMOSD) who have experienced only one relapse tend to underestimate their risk of…
Under normal circumstances, immune B-cells train T-cells, another type of immune cell, on which targets not to attack, preventing the…
Two blood markers — neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) — provide complementary clinical information about…
A new study of disease prevalence estimates that about 22,000 people in the U.S. were living with neuromyelitis optica…
People with neuromyelitis optica spectrum disorder (NMOSD) who switch between treatments more than once because of side effects or…
Ultomiris (ravulizumab) is now approved in Canada to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are…